CTOs on the Move

Halozyme

www.halozyme.com

 
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.halozyme.com
  • 11388 Sorrento Valley Road
    San Diego, CA USA 92121
  • Phone: 858.794.8889

Executives

Name Title Contact Details
Richa Krishnanand
 Senior Director of Technology, Enterprise Analytics and Artificial Intelligence Profile
Cliff Johns
 Senior Director, Information Technology Profile

Funding

Halozyme raised $30M on 02/06/2019
Halozyme raised $15M on 05/14/2020

Similar Companies

Ariana Pharma

Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Notch Therapeutics

Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.